HENGRUI PHARMA - [Overseas Regulatory Announcement - Corporate Governance Related Matters] — 2026032502200

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Jiangsu Hengrui Pharmaceutical Co., Ltd.

(a joint stock limited company incorporated in the People's Republic of China)

(Stock code: 1276)

Overseas regulatory announcement

This announcement is made in accordance with Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

In accordance with the relevant laws and regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceutical Co., Ltd. (the "Company") published the following announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). They are listed below for reference only.

By order of the board of directors

Jiangsu Hengrui Pharmaceutical Co., Ltd.

Chairman

Mr. Sun Piaoyang

Shanghai, China

March 25, 2026

As at the date of this announcement, the members of the Board include (i) executive directors Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Ningjun and Mr. Sun Jieping; (ii) non-executive director Ms. Guo Congzhao; and (iii) independent non-executive directors Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Zhou Jien.

Company code: 600276 Company abbreviation: Hengrui Pharmaceuticals

Jiangsu Hengrui Pharmaceutical Co., Ltd.

2025 Internal Control Evaluation Report

All shareholders of Jiangsu Hengrui Pharmaceutical Co., Ltd.:

In accordance with the provisions of the "Basic Standards for Enterprise Internal Control" and its supporting guidelines and other internal control regulatory requirements (hereinafter referred to as the Enterprise Internal Control Standard System), combined with the company's (hereinafter referred to as the company's) internal control system and evaluation methods, and on the basis of daily supervision and special supervision of internal control, we evaluated the effectiveness of the company's internal control on December 31, 2025 (the base date of the internal control evaluation report).

1. Important Statement

In accordance with the provisions of the enterprise's internal control normative system, it is the responsibility of the company's board of directors to establish, improve and effectively implement internal control, evaluate its effectiveness, and truthfully disclose the internal control evaluation report. The Supervisory Board supervises the establishment and implementation of internal controls by the Board of Directors. Managers are responsible for organizing and leading the daily operation of the enterprise's internal controls. The company's board of directors, board of supervisors, directors, supervisors and senior management personnel guarantee that there are no false records, misleading statements or major omissions in this report, and bear individual and joint legal responsibility for the authenticity, accuracy and completeness of the report content.

The goal of the company's internal control is to reasonably ensure legal compliance of operation and management, asset safety, authenticity and completeness of financial reports and related information, improve operating efficiency and effectiveness, and promote the realization of development strategies. Due to the inherent limitations of internal control, it can only provide reasonable assurance for achieving the above objectives. In addition, since changes in circumstances may cause internal controls to become inappropriate, or the degree of compliance with control policies and procedures to be reduced, there is a certain risk in inferring the effectiveness of future internal controls based on the results of internal control evaluations.

2. Conclusion of internal control evaluation

3. Whether the company has any major deficiencies in the internal control of financial reporting on the base date of the internal control evaluation report

□Yes √No

2. Conclusion of the evaluation of internal control over financial reporting

√Valid □Invalid

According to the identification of major deficiencies in the company's internal control over financial reporting, there were no major deficiencies in internal control over financial reporting on the base date of the internal control evaluation report. The board of directors believes that the company has maintained effective internal control over financial reporting in all major aspects in accordance with the requirements of the corporate internal control standard system and relevant regulations.

3. Whether significant deficiencies in internal control over non-financial reporting have been discovered

□Yes √No

According to the identification of major deficiencies in the company's internal control over non-financial reporting, the company found no major deficiencies in internal control over non-financial reporting on the base date of the internal control evaluation report.

4. Factors affecting the conclusion of the internal control effectiveness evaluation from the base date of the internal control evaluation report to the issuance date of the internal control evaluation report □ Applicable √ Not applicable

There are no factors that affect the conclusion of the internal control effectiveness evaluation between the base date of the internal control evaluation report and the issuance date of the internal control evaluation report.

5. Whether the internal control audit opinion is consistent with the company’s evaluation conclusion on the effectiveness of internal control over financial reporting

√Yes □No

6. Is the disclosure of major deficiencies in non-financial reporting internal control in the internal control audit report consistent with the disclosure in the company’s internal control evaluation report √ Yes □ No

7. Internal control evaluation work

(1). Scope of internal control evaluation

The company determines the main units, businesses and matters as well as high-risk areas included in the evaluation scope in accordance with the risk-oriented principle.

1. The main units included in the evaluation scope include: the parent company (aggregated and consolidated settlement center) and 26 first-level subsidiaries.

2. Proportion of units included in the evaluation scope:

Indicator proportion (%)

Ratio of the total assets of the units included in the evaluation scope to the total assets of the company's consolidated financial statements 100 Ratio of the total operating income of the units included in the evaluation scope to the total operating income of the company's consolidated financial statements 100

3. The main businesses and matters included in the evaluation scope include:

Organizational structure, development strategy, human resources, social responsibility, corporate culture, financial activities, procurement business, asset management, sales business, research and development, engineering projects, financial reporting, contract management, information systems, etc.

4. High-risk areas of focus include:

Sales risks, R&D risks, product quality risks, production management risks, financial reporting risks, human resources risks, safety risks, etc.

5. The above-mentioned units, businesses, matters and high-risk areas included in the evaluation scope cover the main aspects of the company’s operation and management. Are there any major omissions?

□Yes √No

6. Whether statutory exemptions exist

□Yes √No

7. Other instructions

None

(2). Basis for internal control evaluation and identification standards for internal control deficiencies

The company organizes and carries out internal control evaluation work based on the enterprise's internal control standard system and the company's various internal control systems and processes.

1. Whether the specific identification standards for internal control deficiencies have been adjusted from previous years

□Yes √No

The company's board of directors distinguished between financial reporting internal control and non-financial reporting internal control based on the company's internal control standard system's identification requirements for major defects, important defects and general defects, combined with company size, industry characteristics, risk preference and risk tolerance and other factors, and studied and determined the specific identification standards for internal control defects applicable to the company, which are consistent with previous years.

2. Standards for identifying deficiencies in internal control over financial reporting

The quantitative standards for the evaluation of internal control deficiencies over financial reporting determined by the company are as follows:

Indicator name Major defect quantitative standard Important defect quantitative standard General defect quantitative standard Potential misstatement of operating income ≥ 0.5% of total operating income ≤ 1% of total operating income Misstated < 0.5% of total operating income Misstated < 0.5% of total operating income

1%

Potential misstatement of total profit ≥ 5% of total profit 3% of total profit ≤ misstatement < misstatement < 3% of total profit 5% of total profit

Description:

None

The qualitative standards for the evaluation of internal control deficiencies over financial reporting determined by the company are as follows:

Defect nature qualitative criteria

Major deficiencies (1) Ineffective control environment;

(2) The company's directors, supervisors and senior managers committed fraud and caused significant losses and adverse effects to the company; (3) The certified public accountant discovered that there was a major misstatement in the current financial report, but the internal control failed to detect the misstatement during the operation;

(4) Important deficiencies that have been discovered and reported to management are not corrected within a reasonable time;

(5) The audit committee and internal audit department are ineffective in supervising the company’s internal controls.

Important deficiencies (1) Failure to select and apply accounting policies in accordance with generally accepted accounting principles;

(2) Failure to establish anti-fraud procedures and control measures;

(3) Single or multiple deficiencies occur in the financial reporting process. Although the standards for identifying major deficiencies are not met, the

Influence financial reporting to achieve true and accurate goals.

General defects General defects refer to other control defects other than the above-mentioned major defects and important defects.

Description:

None

3. Standards for identifying deficiencies in internal control over non-financial reporting

The quantitative standards for the evaluation of non-financial reporting internal control deficiencies determined by the company are as follows:

Indicator Name Important Defect Quantitative Standard General Defect Quantitative Standard

0.5% of net assets ≤ direct property loss <

Direct property loss Direct property loss <0.5% of net assets

1% of net assets

Description:

None

The qualitative standards for the evaluation of non-financial reporting internal control deficiencies determined by the company are as follows:

Defect nature qualitative criteria

Major defects: If the probability of occurrence of the defect is high, it will seriously reduce the work efficiency or effect, or seriously increase the uncertainty of the effect.

Qualitative or serious deviation from expected goals is a major flaw.

Important defects: If the probability of occurrence of the defect is high, it will significantly reduce the work efficiency or effect, or significantly increase the inefficiency of the effect.

Certainty or significant deviation from expected goals are important flaws. General defects: If the probability of occurrence of defects is small, it will reduce work efficiency or effect, or increase the uncertainty of effect.

Or causing it to deviate from the expected goal is a general defect. Description:

None

(3). Identification and rectification of internal control deficiencies

1. Identification and rectification of internal control deficiencies over financial reporting

1.1. Major defects

Did the company have any major deficiencies in internal control over financial reporting during the reporting period Yes √ No

1.2. Important defects

Does the company have any important deficiencies in internal control over financial reporting during the reporting period? Yes √ No

1.3. General defects

None

1.4. After the above rectifications, as of the base date of the internal control evaluation report, does the company have any significant internal control issues over financial reporting that have not been rectified?

Defects

□Yes √No

1.5. After the above rectifications, as of the base date of the internal control evaluation report, does the company have any important internal control issues over financial reporting that have not been rectified?

Defects

□Yes √No

2. Identification and rectification of internal control deficiencies in non-financial reporting

2.1. Major defects

Did the company discover any major deficiencies in non-financial reporting internal control during the reporting period Yes √ No

2.2. Important flaws

Did the company discover any important deficiencies in non-financial reporting internal control during the reporting period Yes √ No

2.3. General defects

None

2.4. After the above rectifications, on the base date of the internal control evaluation report, has the company discovered any major non-financial reporting internal control issues that have not been rectified?

big flaw

□Yes √No

2.5. After the above rectifications, on the base date of the internal control evaluation report, has the company discovered any important deficiencies in the internal control of non-financial reporting that have not yet been rectified?

□Yes √No

4. Description of other major matters related to internal control

5. Rectification of internal control deficiencies in the previous year

□Applicable √Not applicable

2. Internal control operation status this year and improvement directions for the next year

□Applicable √Not applicable

3. Description of other significant matters

□Applicable √Not applicable

Chairman (authorized by the board of directors): Sun Piaoyang Jiangsu Hengrui Pharmaceutical Co., Ltd.

March 25, 2026